Scinai Immunotherapeutics Ltd. (SCNI)
SCNI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/0001213900-26-038011-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SCNI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | 2015 |
| SEC CIK | 0001611747 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.3M |
| Net income | -$8.3M |
| Operating income | -$7.5M |
| Net margin | -633.6% |
| Operating margin | -575.3% |
| Revenue growth | +99.2% |
| Cash | $1.7M |
| Total assets | $11.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, there is substantial doubt about our ability to continue as a going concern." | 20-F 2026-04-01 |
| Cash and burn | $1.7M cash; operating cash flow -$1.5M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2026-08-21 | Source 2026-08-21 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-28 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ziv Haft Certified Public Accountants (Isr.), Tel Aviv, Israel | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $1.3M | -$8.3M | -$6.0M | $1.7M | No debt tags | $1.3M | 20-F 2026-04-01 |
| Q1 2023 2023-03-31 | Not filed | -$3.5M | -$3.1M | $10.8M | No debt tags | Needs four quarters | 10-Q 2023-05-15 |
| Q1 2022 2022-03-31 | Not filed | -$2.5M | -$1.1M | $15.4M | No debt tags | Needs four quarters | 10-Q 2023-05-15 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-11-10 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-04-01 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-09 |
| Latest current report CURRENT REPORT | 8-K | 2023-06-08 |
Source: SEC EDGAR submissions feed, 498 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.3% |
| 1 month | -67.5% |
| 3 months | -83.3% |
| Year to date | -94.4% |
| 1 year | -96.0% |
| From 52-week high | -96.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SLXN | Silexion Therapeutics Corp | $1.76 | -11.11% | $1.1M |
| CLDI | Calidi Biotherapeutics Inc. | $0.6023 | -3.15% | $2.2M |
| VIVS | VivoSim Labs Inc. | $0.1237 | -2.68% | $2.5M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| LIMN | Liminatus Pharma Inc. | $2.97 | -0.67% | $4.0M |
| CRIS | Curis Inc. | $0.4358 | -2.07% | $4.1M |
| BTTC | Black Titan Corporation | $0.2873 | -9.20% | $4.3M |
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier